Cargando…
Addressing the implementation gap in advanced therapeutics for spinal muscular atrophy in the era of newborn screening programs
Spinal muscular atrophy (SMA) is a rare genetic disease that results in progressive neuromuscular weakness. Without therapy, the most common form of the disease, type 1, typically results in death or chronic respiratory failure in the first 2 years of life. Thanks to the recent introduction of newbo...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790909/ https://www.ncbi.nlm.nih.gov/pubmed/36578307 http://dx.doi.org/10.3389/fneur.2022.1064194 |